Hearts previously rejected due to donors’ age or other risk factors can now be declared viable for transplantation using pharmacological stress echo, according to research presented at EUROECHO and other Imaging Modalities 2012. The study was presented by Dr Tonino Bombardini from Pisa, Italy.
Heart transplantation is an established procedure in patients with end-stage heart failure but it is limited by a severe donor organ shortage. The average age of organ donors has increased and the donor is frequently a patient who died of a stroke. Every year in Europe a pool of
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:532020-08-26 14:42:16Rejected hearts now viable for transplantation after stress echo
Nanodiamonds bound to the chemotherapy drug epirubicin are enclosed within a lipid membrane and coupled to antibodies specific to hard-to-treat tumors.
Recently, doctors have begun to categorise breast cancers into four main groups according to the genetic makeup of the cancer cells. Which category a cancer falls into generally determines the best method of treatment.
But cancers in one of the four groups
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:532020-08-26 14:41:57UCLA researchers find nanodiamonds could improve effectiveness of breast cancer treatment
Chemists have developed a prototype medical dressing that detects the first signs of the lethal Toxic Shock Syndrome along with other burn wound infections and could potentially save the lives of children with serious burns.
Toxic Shock Syndrome (TSS) is a serious complication of burn infections and particularly dangerous in children under four due to their immature immune systems. Left untreated, a child with a relatively small burn who develops TSS can rapidly deteriorate within a few hours. If left untreated, fifty per cent of children with the full-blown disease can die.
Scientists at the University of Bath have been working with clinicians at the South West Paediatric Burns Centre at Frenchay Hospital in Bristol to create an advanced wound dressing that can detect key microbial pathogens including the bacteria which cause TSS.
They have now developed a prototype dressing that releases dye from nano-capsules triggered by the presence of disease-causing pathogenic bacteria. The dye fluoresces under ultraviolet (UV) light, alerting healthcare professionals that the wound is infected.
The nano-capsules mimic skin cells in that they only break open when toxic bacteria are present, not responding to the harmless bacteria that normally live on healthy skin.
Dr Toby Jenkins, Reader in Biophysical Chemistry at Bath, is leading the project. He explained: ‘Around 5,000 children a year in England and Wales are hospitalised or treated in hospital with serious burns, mostly scalds caused by tea and coffee.
‘The big problem for clinicians is the fast diagnosis of infection. Current methods take between 24 and 48 hours to get an answer as to whether the wound is infected.
‘However our burns dressing gives a simple colour change under UV light if a pathogenic, disease-causing bacteria is present in the burn, meaning clinicians can be alerted quickly to a potential infection.’
Dr Amber Young, Consultant Paediatric Anaesthetist at the South West Paediatric Burns Centre at Frenchay Hospital and Paediatric Clinical Lead South West UK Burn Care Network, is the clinical consultant on the project. She said: ‘At the moment when a child with a small burn develops a high temperature we have no easy way of knowing if the child has a serious bacterial infection, or simply a cough or cold.
‘We currently have to remove the dressing to test for infection, which may result in slower healing and potentially life-long scarring, and is very distressing for the child. This new dressing will mean we will be able to detect the early signs of infection so we can diagnose and treat the child quickly.
‘It could make a real difference to the lives of many thousands of children.’
The prototype has been tested on skin samples in the lab and is currently being optimised for stability and shelf-life. The researchers expect to start safety trials on healthy human volunteers in four years.
University of Bath
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:532020-08-26 14:42:00Revolutionary burns dressing could save young lives
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:532020-08-26 14:42:04Infant born with HIV reportedly cured
A multi-site clinical trial including the University of Colorado Cancer Center shows that the benefit of Bright IDEAS problem-solving skills training goes beyond teaching parents to navigate the complex medical, educational, and other systems that accompany a child
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:532020-08-26 14:42:08Study shows that problem-solving training helps mothers cope with child?s cancer diagnosis
Blind mice can see again, after Oxford University researchers transplanted developing cells into their eyes and found they could re-form the entire light-sensitive layer of the retina.
The researchers say the approach has relevance for treating patients with retinitis pigmentosa, a condition in which the light-sensing cells in the retina gradually die leading to progressive blindness.
The study was led by Professor Robert MacLaren in the Nuffield Department of Clinical Neurosciences at the University of Oxford, together with Dr Mandeep Singh, an eye surgeon from the National University Hospital of Singapore who is currently undertaking PhD studies in Oxford
The researchers worked with mice that are blind due to complete loss of the light-sensing photoreceptor cells in their retinas. This is the most relevant mouse model for treating patients who are blind from retinitis pigmentosa.
After two weeks, the researchers showed the cells transplanted into the eye had re-formed a full light-detecting layer on the retina and the mice could see.
The cells used were mouse ‘precursor’ cells that are on an initial path towards developing into retinal cells.
A pupil constriction test showed that, of the 12 mice that received the cell transplant, 10 showed improved pupil constriction in response to light. This shows that the retinas of the mice were sensing the light once more, and this was being transmitted down the optic nerve to the brain.
Dr Singh says: ‘We found that if enough cells are transplanted together, they not only become light sensing but they also regenerate the connections required for meaningful vision.’
Dr Mandeep Singh Professor MacLaren explains: ‘Stem cells have been trialled in patients to replace the pigmented lining of the retina, but this new research shows that the light-sensing layer might also be replaced in a similar way. The light-sensing cells have a highly complex structure and we observed that they can resume function as a layer and restore connections after transplantation into the completely blind retina.’
In looking forward towards potential cell treatments for blindness in humans, Professor MacLaren explains that they would like to use induced pluripotent stem cells, or iPS cells. These are stem cells that have been generated from the patient
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:532020-08-26 14:42:12New stem cell approach for blindness successful in mice
Amid increasing fear of overexposure to radiation from CT scans, a panel of experts has recommended more research on the health effects of medical imaging and ways to reduce unnecessary CT tests, as well as industry standardisation of CT machines.
The recommendations were developed at the Radiation Dose Summit, organised by the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The summit included more than 100 medical physicists, radiologists, cardiologists, engineers, industry representatives and patient advocates. The proceedings, held in Bethesda, MD in early 2011, covered currently understood risks of radiation exposure from CT scans, set priorities for future research, and called for changes to industry practices.
‘The number of CT exams in the U.S. has increased by about 10 percent each year over the past decade,’ said John Boone, UC Davis professor of radiology and lead author of the Radiology article. ‘This trend underscores the importance of developing a better understanding of the health risks of radiation exposure versus the benefits of enhanced diagnosis.’
The experts conceded that despite widespread public concern about radiation risks, the biologic effects from medical imaging tests are not entirely understood. Most direct evidence comes from the effects of instantaneous, high-dose, whole-body exposures due to industrial accidents and from survivors of the atomic bombs in Hiroshima and Nagasaki, Japan. Whether these findings can be extrapolated to people exposed to occasional and much smaller dosages applied to only parts of the body is uncertain.
‘The standards regarding ‘safe levels’ of radiation were designed for workplace safety and are very conservative,’ said Boone. ‘We don’t know whether the established thresholds are really meaningful for exposure from medical testing.’
The experts pointed out that because there is a high background incidence of cancer world-wide, the small incremental increase in cancer that may be attributable to low doses of radiation from medical imaging is extremely difficult to ascertain. They stated that national and international registries that track cancers and patient exposures to medical radiation may one day make it possible to conduct large epidemiological studies that could help make such associations.
‘In reaction to media coverage of radiation overexposure cases, some patients refuse to undergo medical imaging procedures,’ said Boone. ‘Yet for almost all patients, the risks of foregoing a needed medical procedure far outweigh any potential radiation-associated risks.’
Even accurately recording patient exposures of radiation from medical imaging is extremely difficult, according to the authors. Although it is easy to ascertain how much radiation a machine administers during an imaging study, the amount actually received by a patient depends on various factors including body size. For example, because of differences in body mass, children and small adults can receive a dose of radiation two to three times that of larger people, even when the dose administered is the same.
Other factors, such as whether the patient lies on a moving or stationary table, also affect the radiation dose received. Federally sponsored research is needed to develop methods to more accurately measure patient exposures from different types of CT scans, the authors suggested.
UC Davis Comprehensive Cancer Center
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:532020-08-26 14:42:16UC Davis radiology expert leads published review of radiation exposure risks from medical tests
Johns Hopkins scientists have created a free, Web-based tool to help patients decide whether it’s best to accept an immediately available, but less-than-ideal deceased donor kidney for transplant, or wait for a healthier one in the future.
Historically, the researchers say, it has been difficult, if not impossible, to accurately quantify the risk of accepting a deceased-donor kidney that may have been infected by hepatitis C, as compared to waiting what could be months or years for a better organ. There is a 5 to 15 percent chance of dying every year on the waiting list. Often, organs that may have been at risk of infection are thrown away and never transplanted.
In a new study the Johns Hopkins researchers showed there are some types of patients for whom survival benefit outweighs the risks of accepting a possibly infected organ. They then developed a Web-based mathematical model to help predict which patients they would be. The easy-to-use website can be found at www.transplantmodels.com/ird.
‘Because the supply of the healthiest donor organs is too small, patients need to consider all organ offers or risk dying while waiting for an organ. But this is a very hard decision, and many people turn down transplant offers that, in reality, would provide them significant benefit. Often they would have done much better taking the organ at hand than waiting for the next available one,’ says study leader Dorry L. Segev, M.D., Ph.D., an associate professor of surgery at the Johns Hopkins University School of Medicine. ‘This is the most important decision of a transplant candidate’s life, and we have developed a novel tool we believe can help patients make the best choice.’
EurekAlert
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:532020-08-26 14:41:57Take a kidney transplant now or wait for a better one? Hopkins researchers create ‘decision’ tool
The European Society of Anaesthesiology (ESA) is to launch a safety starter kit containing a wide variety of essential resources to help raise safety standards in anaesthesiology across Europe. The kit will be distributed on a memory stick at this year
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:532020-08-26 14:42:01ESA launches safety kit to help raise anaesthesia safety standards across Europe
Clinical trial results published this week offer additional evidence that a new device may help relieve chronic heartburn symptoms that standard treatment cannot. The Keck Medical Center of USC was one of 14 U.S. and European medical centres to test the device prior to its March 2012 approval by the U.S. Food and Drug Administration.
John Lipham, M.D., associate professor of surgery at the Keck School of Medicine of USC, led clinical investigation of the device at USC as part of his ongoing work to find alternative ways to treat gastroesophageal reflux disease (GERD), or chronic heartburn.
‘These results show that there is another option for the millions of people suffering from chronic reflux,’ Lipham said. ‘Currently, the Keck Medical Center of USC is one of only 30 sites in the country certified to implant the device.’
The LINX Reflux Management System, manufactured by Minnesota-based Torax Medical, Inc., is like a bracelet made up of magnetic, titanium beads implanted around the end of the oesophagus, where the lower oesophageal sphincter is located. The lower oesophageal sphincter is the valve that prevents reflux, and GERD develops when this valve is weakened.
Implantation of the device is potentially an outpatient procedure that can be completed in 15 to 20 minutes, Lipham said.
Lipham and his colleagues assessed 100 patients with GERD before and after surgery, finding that acid reflux decreased, reflux symptoms improved and the use of medication to manage those symptoms decreased for most patients. Severe regurgitation was eliminated in all patients. More than 9 in 10 patients reported satisfaction with their overall condition after having the procedure, compared to 13 percent before treatment while taking medication.
Follow-up studies are still required to assess long-term safety.
Lipham says the LINX device is best for patients with mild to moderate reflux that cannot be adequately controlled by medication or for patients who do not want to take medication to manage the disease. More than 60 million Americans experience heartburn at least once a month and some studies have suggested that more than 15 million experience heartburn symptoms every day, according to the American College of Gastroenterology.
Surgical treatment of reflux disease had been limited to a procedure called a Nissen fundoplication, which involves recreating the oesophageal sphincter. While fundoplication is recommended for those with severe reflux, it is a complicated procedure that prevents the ability to belch or vomit and often leads to bloating or gas problems.
The most common adverse events experienced with the LINX included difficulty swallowing, pain when swallowing food, chest pain, vomiting, and nausea. It is important to note that patients with LINX will no longer be able to undergo magnetic resonance imaging (MRI) procedures. The magnetic beads interfere with the machine and can cause the device to be damaged and the patient to be injured.
Keck Medical Center
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:532020-08-26 14:42:04Keck Medical Center of USC offers new treatment for chronic reflux disease
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.